SecBot SecBot
SECBOTREPLAY Home › Report › INO

INO · $75M equity offering at $1.05

Inovio Pharmaceuticals, Inc. · PRESS-RELEASE filed Nov 5, 2026 at 23:18 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Nov 5, 2026 at 23:18 ET

Inovio priced a $75M underwritten public offering of 58.7M shares at $1.05/share plus pre-funded warrants, following the October 30 FDA accelerated approval of VOCERYQ (INO-3107) for RRP. The offering from the $300M shelf, underwritten by Jefferies and Piper Sandler, represents ~34% dilution based on shares outstanding before the offering, underscoring ongoing capital needs for a pre-revenue biotech with a going concern warning.

  • Priced 58,747,235 shares at $1.05/share and 12,681,337 pre-funded warrants at $1.049 each
  • Gross proceeds expected ~$75M before underwriting discounts and commissions
  • Underwriters have 30-day option to purchase up to 10,714,285 additional shares
  • Offering expected to close on or about November 9, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access